1. Home
  2. CTS vs ATAI Comparison

CTS vs ATAI Comparison

Compare CTS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTS Corporation

CTS

CTS Corporation

HOLD

Current Price

$59.13

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$3.98

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTS
ATAI
Founded
1896
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
CTS
ATAI
Price
$59.13
$3.98
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$15.88
AVG Volume (30 Days)
215.5K
6.7M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
0.29%
N/A
EPS Growth
15.87
N/A
EPS
0.59
N/A
Revenue
$541,318,000.00
$4,089,000.00
Revenue This Year
$5.55
N/A
Revenue Next Year
$5.00
N/A
P/E Ratio
$101.42
N/A
Revenue Growth
4.95
1227.60
52 Week Low
$36.03
$1.66
52 Week High
$60.82
$6.73

Technical Indicators

Market Signals
Indicator
CTS
ATAI
Relative Strength Index (RSI) 67.96 46.94
Support Level $41.09 $3.41
Resistance Level $59.66 $4.24
Average True Range (ATR) 2.11 0.33
MACD 0.29 -0.06
Stochastic Oscillator 79.12 5.90

Price Performance

Historical Comparison
CTS
ATAI

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: